Skip to main content

Table 1 High-risk criteria for treatment of mild to moderate COVID-19 in pediatric patients

From: The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series

• Body mass index (BMI) ≥ 85th percentile

• Chronic kidney disease

• Diabetes

• Immunosuppressive disease or Immunosuppressive therapy

• Chronic lung disease (e.g. chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)

• Neurodevelopmental disorders

• Cardiovascular disease (including congenital heart disease) or hypertension

• Medical-related technological dependence